Correlation Between Inozyme Pharma and Vaxcyte
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Vaxcyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Vaxcyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Vaxcyte, you can compare the effects of market volatilities on Inozyme Pharma and Vaxcyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Vaxcyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Vaxcyte.
Diversification Opportunities for Inozyme Pharma and Vaxcyte
0.43 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Inozyme and Vaxcyte is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Vaxcyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vaxcyte and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Vaxcyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vaxcyte has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Vaxcyte go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Vaxcyte
Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Vaxcyte. In addition to that, Inozyme Pharma is 1.88 times more volatile than Vaxcyte. It trades about -0.27 of its total potential returns per unit of risk. Vaxcyte is currently generating about -0.06 per unit of volatility. If you would invest 8,199 in Vaxcyte on December 28, 2024 and sell it today you would lose (1,122) from holding Vaxcyte or give up 13.68% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 98.36% |
Values | Daily Returns |
Inozyme Pharma vs. Vaxcyte
Performance |
Timeline |
Inozyme Pharma |
Vaxcyte |
Inozyme Pharma and Vaxcyte Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Inozyme Pharma and Vaxcyte
The main advantage of trading using opposite Inozyme Pharma and Vaxcyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Vaxcyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxcyte will offset losses from the drop in Vaxcyte's long position.Inozyme Pharma vs. Day One Biopharmaceuticals | Inozyme Pharma vs. X4 Pharmaceuticals | Inozyme Pharma vs. Acumen Pharmaceuticals | Inozyme Pharma vs. Mereo BioPharma Group |
Vaxcyte vs. Larimar Therapeutics | Vaxcyte vs. Syndax Pharmaceuticals | Vaxcyte vs. Merus BV | Vaxcyte vs. Sutro Biopharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Complementary Tools
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |